IRCT20221211056775N1 IRCT 2022-12-18 Arak University of Medical Sciences The effect of rifaximin in IBS Investigating the effect of rifaximin tablets on the quality of life and symptoms of irritable bowel syndrome in patients 2023-01-10 anticipated 60 Complete https://irct.ir/trial/67364 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Blinding description: This study will be conducted in a double-blind manner. In this way, participating patients and clinical caregivers and outcome assessors are not aware of the study groups and know them only based on the letters A and B. Of course, the main researcher and data analyst are aware of the studied groups and the interventions performed in them. 3 Irritable bowel syndrome. Intervention 1: Intervention group: 30 patients fill out the questionnaire related to the quality of life of irritable bowel syndrome 2 weeks before starting to take rifaximin tablets and record the symptoms they had before starting the drug. Since the beginning of the study, rifaximin 550 mg tablets (Kowsar-Iran) have been taken orally every 12 hours, once a day. Then, 2 weeks after taking the drug, they fill out the quality of life questionnaire again. Intervention 2: Control group: 30 patients fill out the irritable bowel syndrome quality of life questionnaire 2 weeks before starting the placebo pill and record the symptoms they had before starting the drug. Since the beginning of the study, placebo pills, similar to the medicine of the intervention group, have been taken orally every 12 hours, one tablet per day. Then, 2 weeks after taking the drug, they fill out the quality of life questionnaire again. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information.